CRF and SCAI Present an
In-Depth TAVR Series

TAVR at the Crossroads:

Transitioning to a Mainstream Therapy

Thursday, May 5, 2016

Lunch Program

11:30 am: Check-in & Lunch
12:00 pm-1:00 pm: Program

Hyatt Regency Orlando
Room: Celebration 5/6
9801 INTERNATIONAL DRIVE
ORLANDO, FL 32819

TAVR In the
Real World:

Practice Standards and
New Clinical Indications

Friday, May 6, 2016

Lunch Program

11:30 am: Check-in & Lunch
12:00 pm-1:00 pm: Program

Hyatt Regency Orlando
Room: Orlando Ballroom M
9801 INTERNATIONAL DRIVE
ORLANDO, FL 32819


TAVR at the Crossroads:

Transitioning to a
Mainstream Therapy

Thursday, May 5, 2016

Learning Objectives

By the end of this program, participants should be able to:

  1. Define the current role of TAVR as the gold standard for high-risk patients and identify when it is preferred to surgery
  2. Interpret new data indicating TAVR as an appropriate treatment option for intermediate-risk patients
Faculty

Chairs

George D. Dangas, MD, PhD, FSCAI
Mount Sinai Medical Center
New York, NY

Martin B. Leon, MD, FSCAI
NewYork-Presbyterian Hospital /
Columbia University Medical Center
New York, NY

Invited Faculty

Robert J. Applegate, MD, FSCAI
Wake Forest University School of Medicine
Winston-Salem, NC

Ted Feldman, MD, FSCAI
Evanston Hospital
Evanston, IL

Michael Reardon, MD
Houston Methodist Hospital
Houston, TX

Molly Szerlip, MD, FSCAI
The Heart Hospital Baylor
Plano, TX

Agenda
12:00 pm
TAVR is Established in High-Risk Patients: Lessons From the TVT Registry Molly Szerlip, MD, FSCAI
12:10 pm
Discussion
12:20 pm
TAVR Has Arrived in Intermediate-Risk Patients: New Clinical Evidence
Martin B. Leon, MD, FSCAI
12:30 pm
Discussion
12:40 pm
Based on Current Evidence, When Is TAVR the Preferred Alternative: A Surgeon’s Perspective
Michael Reardon, MD
12:50 pm
Discussion
1:00 pm
Adjourn

TAVR In the
Real World:

Practice Standards and
New Clinical Indications

Friday, May 6, 2016

Learning Objectives

By the end of this program, participants should be able to:

  1. Express how outcomes and efficiencies in real-world TAVR practice can be improved
  2. Describe the place for TAVR in new settings, such as treatment of bioprosthetic valve failure and low-risk patients
Faculty

Chairs

Vasilis Babaliaros, MD
Emory University School of Medicine
Atlanta, GA

James B. Hermiller, Jr., MD, FSCAI
St. Vincent Hospital/The Heart Center of Indiana
Indianapolis, IN

Invited Faculty

Eberhard Grube, MD, FSCAI
University Hospital Bonn
Bonn, Germany

Howard C. Herrmann, MD, MSCAI
Hospital of the University of Pennsylvania
Philadelphia, PA

Clifford J. Kavinsky, MD, PhD, FSCAI
Rush University Medical Center
Chicago, IL

Christian Spies, MD, FSCAI
The Queen's Medical Center
Honolulu, HI

Agenda
12:00 pm
Real-World TAVR: Improving Outcomes, Efficiencies, and Economics
Vasilis Babaliaros, MD
12:10 pm
Discussion
12:20 pm
My Perspective: How to Optimize Your TAVR Program in Preparation for Expanded Indications
Christian Spies, MD, FSCAI
12:30 pm
Discussion
12:40 pm
TAVR Gone Viral: Setting the Stage for Low-Risk Patients and Severe Asymptomatic AS
Howard C. Herrmann, MD, MSCAI
12:50 pm
Discussion
1:00 pm
Adjourn

REGISTER

There is no cost to register. You must be a SCAI 2016 registrant to attend these satellite programs.

Should you have any questions, please contact Catherine Brosnan at cbrosnan@crf.org.

Register Now